Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients.

MLA

de Bitter, Tessa J. J., et al. “Comprehensive Clinicopathological and Genomic Profiling of Gallbladder Cancer Reveals Actionable Targets in Half of Patients.” NPJ Precision Oncology, vol. 6, no. 1, Nov. 2022, p. 83. EBSCOhost, https://doi.org/10.1038/s41698-022-00327-y.

APA

de Bitter, T. J. J., de Reuver, P. R., de Savornin Lohman, E. A. J., Kroeze, L. I., Vink-Börger, M. E., van Vliet, S., Simmer, F., von Rhein, D., Jansen, E. A. M., Verheij, J., van Herpen, C. M. L., Nagtegaal, I. D., Ligtenberg, M. J. L., & van der Post, R. S. (2022). Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. NPJ Precision Oncology, 6(1), 83. https://doi.org/10.1038/s41698-022-00327-y

Chicago

de Bitter, Tessa J J, Philip R de Reuver, Elise A J de Savornin Lohman, Leonie I Kroeze, Marianne E Vink-Börger, Shannon van Vliet, Femke Simmer, et al. 2022. “Comprehensive Clinicopathological and Genomic Profiling of Gallbladder Cancer Reveals Actionable Targets in Half of Patients.” NPJ Precision Oncology 6 (1): 83. doi:10.1038/s41698-022-00327-y.